114 related articles for article (PubMed ID: 31267514)
1. Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era.
Prusila REI; Sorigue M; Jauhiainen J; Mercadal S; Postila A; Salmi P; Tanhua T; Tikkanen S; Kakko S; Kuitunen H; Pollari M; Nystrand I; Kuusisto MEL; Vasala K; Jantunen E; Korkeila E; Karihtala P; Sancho JM; Turpeenniemi-Hujanen T; Kuittinen O
Br J Haematol; 2019 Nov; 187(3):364-371. PubMed ID: 31267514
[TBL] [Abstract][Full Text] [Related]
2. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.
Méndez M; Torrente M; Sánchez-Beato M; González-Rincón J; Royuela A; Gómez-Codina J; de la Cruz-Merino L; Rueda A; Llanos M; Quero C; Rodríguez-Abreu D; Gumá J; Monsalvo S; Sabin P; Provencio M
Hematol Oncol; 2019 Apr; 37(2):143-150. PubMed ID: 30840776
[TBL] [Abstract][Full Text] [Related]
3. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.
Casulo C; Day B; Dawson KL; Zhou X; Flowers CR; Farber CM; Hainsworth JD; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW
Ann Oncol; 2015 Nov; 26(11):2311-7. PubMed ID: 26362568
[TBL] [Abstract][Full Text] [Related]
4. Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group.
Hirayama Y; Ishitani K; Ota S; Kurosawa M; Kondo T; Takimoto R; Mori A; Sakai H; Torimoto Y; Yamamoto S; Sato K; Iwasaki H; Kohda K; Ishida T; Kakinoki Y; Fukuhara T; Kato J
Int J Hematol; 2014 Sep; 100(3):281-9. PubMed ID: 25052874
[TBL] [Abstract][Full Text] [Related]
5. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
6. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era.
Rivas-Delgado A; Magnano L; Moreno-Velázquez M; García O; Nadeu F; Mozas P; Dlouhy I; Baumann T; Rovira J; González-Farre B; Martínez A; Balague O; Delgado J; Villamor N; Giné E; Campo E; Sancho-Cia JM; López-Guillermo A
Br J Haematol; 2019 Mar; 184(5):753-759. PubMed ID: 30515755
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
Južnič Šetina T; Borštnar S; Jezeršek Novaković B
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
[TBL] [Abstract][Full Text] [Related]
8. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
Sarkozy C; Maurer MJ; Link BK; Ghesquieres H; Nicolas E; Thompson CA; Traverse-Glehen A; Feldman AL; Allmer C; Slager SL; Ansell SM; Habermann TM; Bachy E; Cerhan JR; Salles G
J Clin Oncol; 2019 Jan; 37(2):144-152. PubMed ID: 30481079
[TBL] [Abstract][Full Text] [Related]
9. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
[TBL] [Abstract][Full Text] [Related]
10. The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy.
Kimby E; Lockmer S; Holte H; Hagberg H; Wahlin BE; Brown P; Østenstad B
Br J Haematol; 2020 Dec; 191(5):738-747. PubMed ID: 32410260
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
[TBL] [Abstract][Full Text] [Related]
12. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
[TBL] [Abstract][Full Text] [Related]
13. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
[TBL] [Abstract][Full Text] [Related]
15. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
[TBL] [Abstract][Full Text] [Related]
16. Haematological cancer: rituximab maintenance improves the outcome of elderly patients with FL.
Jones B
Nat Rev Clin Oncol; 2013 Nov; 10(11):607. PubMed ID: 23999211
[No Abstract] [Full Text] [Related]
17. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.
Cheah CY; Chihara D; Ahmed M; Davis RE; Nastoupil LJ; Phansalkar K; Hagemeister FB; Fayad LE; Westin JR; Oki Y; Fanale MA; Romaguera JE; Wang ML; Lee H; Turturro F; Samaniego F; Rodriguez MA; Neelapu SS; Fowler NH
Ann Oncol; 2016 May; 27(5):895-901. PubMed ID: 26802151
[TBL] [Abstract][Full Text] [Related]
18. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
20. Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study.
Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e172-e183. PubMed ID: 30691994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
